GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (FRA:O1P) » Definitions » Gross Profit

RVL Pharmaceuticals (FRA:O1P) Gross Profit : €26.34 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Gross Profit?

RVL Pharmaceuticals's gross profit for the three months ended in Jun. 2023 was €5.83 Mil. RVL Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was €26.34 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. RVL Pharmaceuticals's gross profit for the three months ended in Jun. 2023 was €5.83 Mil. RVL Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was €7.62 Mil. Therefore, RVL Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 was 76.44%.

RVL Pharmaceuticals had a gross margin of 76.44% for the quarter that ended in Jun. 2023 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of RVL Pharmaceuticals was 88.14%. The lowest was 42.50%. And the median was 53.49%.


RVL Pharmaceuticals Gross Profit Historical Data

The historical data trend for RVL Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Gross Profit Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial 108.66 115.56 20.11 12.29 38.01

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.89 7.57 6.84 6.10 5.83

Competitive Comparison of RVL Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, RVL Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Gross Profit falls into.



RVL Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

RVL Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=46.937 - 8.927
=38.01

RVL Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=7.622 - 1.796
=5.83

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €26.34 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

RVL Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=5.83 / 7.622
=76.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


RVL Pharmaceuticals  (FRA:O1P) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

RVL Pharmaceuticals had a gross margin of 76.44% for the quarter that ended in Jun. 2023 => Durable competitive advantage


RVL Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


RVL Pharmaceuticals (FRA:O1P) Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

RVL Pharmaceuticals (FRA:O1P) Headlines

No Headlines